9.62
+0.24
(2.56%)
May 23 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 9.21 - 9.69 |
| 52 week | 4.00 - 12.70 |
| Open | 9.24 |
| Vol / Avg. | 0.00/381,514.00 |
| Mkt cap | 269.82M |
| P/E | - |
| Div/yield | - |
| EPS | -1.29 |
| Shares | 28.05M |
| Beta | - |
| Inst. own | 44% |
Events
May 8, 2013
Q1 2013 Coronado Biosciences Earnings Conference Call
Apr 9, 2013
Coronado Biosciences Analyst Meeting
Mar 18, 2013
Coronado Biosciences at Roth Conference
Mar 14, 2013
Q4 2012 Coronado Biosciences Earnings Conference Call
Feb 25, 2013
Coronado Biosciences at Citi Global Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -82.20% | -85.79% |
| Return on average equity | -145.73% | -134.14% |
| Employees | 16 | - |
| Carbon Disclosure Rating | - | - |
Address
15 New England Executive Park
BURLINGTON, MA 01803
United States - Map
+1-781-2386621 (Phone)
+1-781-4597788 (Fax)
BURLINGTON, MA 01803
United States - Map
+1-781-2386621 (Phone)
+1-781-4597788 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Coronado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company�s two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn�s disease (Crohn�s), ulcerative colitis (UC) and multiple sclerosis (MS), and CNDO-109, a compound that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells, for the treatment of acute myeloid leukemia (AML). In January 2011, the Company acquired the OvaMed GmbH License.
Officers and directors
| Harlan F. Weisman M.D. | Chairman of the Board, Chief Executive Officer | |
| Eric K. Rowinsky M.D. | Vice Chairman of the Board | |
| Lucy Lu M.D. | Chief Financial Officer, Executive Vice President | |
| Noah D. Beerman | Chief Operating Officer, Executive Vice President | |
| Karin M. Hehenberger M.D., Ph.D. | Executive Vice President and Chief Medical Officer | |
| Dale Ritter | Senior Vice President - Finance, Chief Accounting Officer | |
| David J. Barrett | Independent Director | |
| Jimmie Harvey Jr., M.D. | Independent Director | |
| J. Jay J. Lobell J.D. | Independent Director | |
| Michael W. Rogers MBA | Independent Director |